Bio-Techne (TECH) Proxy filing summary

Executive summary

• Unconditional approval for the proposed acquisition by Merck KGaA, Darmstadt, Germany was received from the German Federal Cartel Office on August 17, 2026.

• The transaction is subject to shareholder approval and other customary closing conditions.

• Forward-looking statements highlight potential risks, including integration challenges, regulatory delays, and market volatility.

Voting matters and shareholder proposals

• Shareholders are urged to review proxy materials and vote on the proposed transaction involving the acquisition.

• Proxy materials, including the Schedule 14A, have been filed with the SEC and are available for review.

Board of directors and corporate governance

• Directors and executive officers of both companies may participate in the solicitation of proxies for the transaction.

• Information about directors, executive officers, and their compensation is available in prior proxy statements and SEC filings.